Drugscan Develops Method to Evaluate Transdermal Patch Capabilities
The study aided pharmaceutical companies in evaluating the effect of fentanyl patches if chewed by an abuser-a common method to release the fentanyl from the patch.
Drugscan Pharmaceutical Services announced that it has developed an in-vitro method to assess the capabilities of transdermal fentanyl patches through an in-vitromastication study. The study aided pharmaceutical companies in evaluating the effect of fentanyl patches if chewed by an abuser-a common method to release the fentanyl from the patch.
According to an Aug. 21, 2019 press release, the company used an in-vitromastication device from their CAT.one laboratory to simulate chewing of a commonly prescribed transdermal fentanyl patch, which is designed to slowly release the opioid through the skin over 72-hours. Researchers found that the patch released dangerous levels of fentanyl within a few minutes of being chewed.
"Fentanyl is a potent synthetic opioid, that when used appropriately, is an effective tool for treating chronic pain-but can very quickly become abused," said Anthony Costantino, PhD, president at Drugscan, and coauthor of the study, in the press release. "This in-vitromodel is far safer, less costly, and substantially faster than performing in-vivoevaluations of oral abuse potential and may assist pharmaceutical developers in evaluating the abuse-deterrent properties of new fentanyl transdermal patches to aid in limiting abuse and counteracting the opioid epidemic."
Source: Drugscan
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
